Healthcare CEOs share 2015 moments that stood out

Michael Walter | | Health Exec | Management

Becker’s Hospital Review received feedback from 20 CEOs in the healthcare industry about which event in 2015 fascinated them the most.

The answers ranged from one sentence to a few paragraphs, from something specifically related to healthcare to a more general news story. It’s certainly worth going through and reading each one.

For example, here’s Lynn Nicholas, Massachusetts Hospital Association president and CEO:

“The King v. Burwell debate before the Supreme Court, which was resolved in June,” Nicholas answered. “In the Commonwealth of Massachusetts we believe strongly in the obligation to provide healthcare coverage for all citizens, having done so since 2006. It was fascinating to watch the arguments unfold, hoping that reasoned law would trump politics in this watershed decision. The fact that naysayers are still tilting at the same windmill with different lances deflects from the task at hand of improving access to care for millions of deserving citizens.”

Click the link below to read the full list:

20 healthcare CEOs name the event that fascinated them most

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Related Content

FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
Anthem BCBS reverses course on anesthesia time limits
FDA issues Class I recall on insulin syringes due to risk of death
FDA issues Class I recall on insertion tubes after manufacturing error

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.